Highlights

  • Immuron (ASX:IMC) reported FY26 global sales Revenue of $7.7 million, up 6% on the prior corresponding period.
  • Australian sales revenue increased 10% to $5.8 million, while US sales revenue rose 7% to $1.8 million.
  • The company reported cash of $9.0 million at FY26 year-end.
  • Immuron completed the Travelan n=851 trial and received FDA approval for the IMM-529 IND.
  • Immuron traded at AUD 0.037, flat at 0.00% during the afternoon Trading session on 28 August 2026.

Immuron Limited (ASX:IMC) has released its FY26 preliminary results, highlighting continued sales growth, progress across clinical programs and a strategic focus on improving profitability and reducing cash burn. The company reported FY26 global sales revenue of $7.7 million, representing a 6% increase on the prior corresponding period.

During the afternoon trading session on 28 August 2026, Immuron (ASX:IMC) was trading at AUD 0.037, flat at 0.00%. The stock remains down 47.14% over the past year.

Financial Performance

Immuron reported FY26 global sales revenue of $7.7 million, with growth supported by its commercial product portfolio.

Australian sales revenue reached $5.8 million, increasing 10% during FY26, while United States sales revenue was $1.8 million, up 7%. US sales revenue increased 13% when measured in US dollar terms.

The company reported a Gross Profit Margin of 64.5%, representing a 0.9% decline during the year. Net profit was reported at negative $3.8 million, reflecting a $1.4 million improvement.

Immuron ended FY26 with cash of $9.0 million, representing a $6.2 million improvement.

Travelan Growth

Travelan remained a key commercial focus for Immuron during FY26, with the company continuing to expand sales across key markets.

The company reported growth across Australian and US markets, with Australian revenue increasing 10% and US revenue increasing 7% during FY26.

Immuron’s FY27 priorities include continued Travelan sales growth, portfolio expansion and geographic sales expansion.

Clinical Progress

During FY26, Immuron achieved several clinical and operational milestones, including FDA approval of the IMM-529 Investigational New Drug (IND) application and completion of the Travelan n=851 trial.

The company also received a new US Department of Defense subaward and launched a new product in Australia.

Immuron engaged Pullan Consulting to support partnering activities for IMM-529 as part of its broader clinical development strategy.

Strategic Focus

Immuron said FY26 included a strategic reset aimed at improving profitability and reducing cash burn.

The company’s focus remains on commercialising oral products for gut-mediated diseases through its technology platform and product portfolio.

The company continues to progress its pipeline opportunities while seeking partnerships to support development and commercialisation activities.

FY27 Outlook

Immuron outlined several priorities for FY27, including continued Travelan sales growth, portfolio expansion, geographic sales expansion and updates regarding partnering activities for IMM-529.

The company expects its cash position to support operations through FY27–FY28 and remains focused on improving profitability and reducing cash burn.

Investor Takeaway

Immuron’s FY26 update highlights sales growth across key markets, progress across clinical programs and a focus on improving operating performance. Investors may continue watching Travelan commercial growth, IMM-529 partnering developments, portfolio expansion and progress towards profitability objectives.